Viatris has initiated a nationwide recall of Xanax XR (alprazolam extended-release) tablets due to a manufacturing issue.
The recall affects 3-milligram tablets packaged in 60-count bottles under lot number 8177156, with an expiration date of Feb. 28, 2027, according to an FDA enforcement report.
The FDA classified the recall as Class II, indicating the product may cause temporary or medically reversible adverse health effects.
The company said the recall was initiated March 17 and stems from failed dissolution specifications, which could affect how the drug releases in the body.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.